Market revenue in 2023 | USD 110.5 million |
Market revenue in 2030 | USD 175.0 million |
Growth rate | 6.8% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 65.7% in 2023. Horizon Databook has segmented the Sweden blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Sweden has been at the forefront of precision medicine initiatives, strongly emphasizing personalized treatment approaches. This drives the demand for advanced diagnostic tests identifying specific biomarkers and genetic mutations associated with blood cancer.
Blood Cancer awareness programs play a crucial role in educating public about the risks associated with prevalence and the importance of early detection. Hence, these programs are vital for reducing the incidence of blood cancer.
The Swedish government has launched several initiatives to improve cancer care, including the National Cancer Strategy and the Genomic Medicine Sweden initiative. These programs promote early detection, precision diagnostics, and personalized treatment for various cancers, including blood cancers.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Sweden blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account